Coherus Oncology (CHRS) Net Shares Issued and Repurchased (2012 - 2025)

Coherus Oncology has disclosed Net Shares Issued and Repurchased across 13 years of filings, most recently posting $6.3 million for Q4 2025.

• In Q4 2025, Net Shares Issued and Repurchased fell 40.49% year-over-year to $6.3 million; the TTM figure through Dec 2025 stood at $6.3 million (down 40.49% YoY), while the FY2025 annual figure was $6.3 million, down 40.49% from the prior year.
• Net Shares Issued and Repurchased came in at $6.3 million for Q4 2025 at Coherus Oncology, down from $10.5 million in the prior quarter.
• In the past five years, Net Shares Issued and Repurchased ranged from a high of $10.5 million in Q4 2024 to a low of $4.6 million in Q4 2021.
• Average Net Shares Issued and Repurchased over 5 years is $6.4 million, with a median of $5.9 million recorded in 2023.
• Year-over-year, Net Shares Issued and Repurchased soared 76.77% in 2024 and tumbled 40.49% in 2025.
• Over 5 years, Net Shares Issued and Repurchased stood at $4.6 million in 2021, then increased by 2.78% to $4.7 million in 2022, then climbed by 26.93% to $5.9 million in 2023, then soared by 76.77% to $10.5 million in 2024, then plunged by 40.49% to $6.3 million in 2025.
• Per Business Quant data, the three most recent Net Shares Issued and Repurchased figures were $6.3 million in Q4 2025, $10.5 million in Q4 2024, and $5.9 million in Q4 2023.